The Bench-to-Bedside (B2B) Program funds research teams seeking to translate basic scientific findings into therapeutic interventions for patients and to increase understanding of important disease processes.
The B2B Program accomplishes this mission by addressing barriers, such as the traditional silos between basic and clinical researchers in biomedical research, which can hinder progress toward finding new therapeutics for patients in need. B2B teams involve basic and clinical researchers, often from different NIH Institutes and Centers. In 2006, the B2B program's charge was expanded to unite the efforts of intramural and extramural NIH researchers. Intramural science refers to research that takes place on an NIH campus under the auspices of federal employees, while extramural research is funded by NIH and conducted by investigators and institutions outside of NIH.
The B2B program exemplifies the benefits associated with intramural – extramural collaborations; the extramural community gains access to the Clinical Center's unique resources, and the intramural community can pursue innovative research with extramural investigators.
ORDR Co-funded Bench-to-Bedside Awards for Rare Diseases